Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
File version
Version of Record (VoR)
Author(s)
Behrens, F
Orbai, A
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
Nash P, Behrens F, Orbai A, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open 2018;4:e000692. doi: 10.1136/rmdopen-2018-000692 This article has been corrected since it first published. There were some copyediting errors which have been rectified now.
Journal Title
RMD Open
Conference Title
Book Title
Edition
Volume
5
Issue
1
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial.
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Science & Technology
Life Sciences & Biomedicine
Rheumatology
Persistent link to this record
Citation
Nash, P; Behrens, F; Orbai, A, Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors (vol 4, e000692, 2018), RMD Open, 2019, 5 (1)